Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you treat a completely resected Stage IA NSCLC EGFR exon 19 with adjuvant osimertinib alone omitting chemotherapy?
Related Questions
What is your experience with transesophageal lung mass biopsies?
How do you transition between TKIs for stage IV NSCLC with actionable mutations?
How would you approach treatment for EGFR-mutant NSCLC with acquired ERBB2 mutation and amplification as resistance to prior osimertinib-based therapy?
Are you using maintenance lurbinectedin with immunotherapy in the first-line treatment of extensive stage small cell lung cancer?
How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?
When do you recommend incorporating HER2 testing into the diagnostic pathway for tumor types where HER2 overexpression is not commonly assessed?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
How do you typically approach adjuvant therapy for a Masaoka stage IVa thymoma post-R0 resection?
How would you manage a patient with metastatic NSCLC and high-level MET amplification who achieved a near CR on tepotinib but is unable to tolerate dose-reduced tepotinib?
